• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Med Virol . Changes in ANA Positivity Following SARS-CoV-2 Outbreak in Lombardy Region, Italy

tetano

Editor, Senior Moderator
J Med Virol


. 2026 Apr;98(4):e70927.
doi: 10.1002/jmv.70927.
Changes in ANA Positivity Following SARS-CoV-2 Outbreak in Lombardy Region, Italy

Eugenio Capparelli[SUP] 1 2 [/SUP], Dennis Maggiolini[SUP] 3 4 [/SUP], Massimo De Paschale[SUP] 5 [/SUP], Claudia Pavia[SUP] 5 [/SUP], Paola Faggioli[SUP] 1 [/SUP], Miriam Colombo[SUP] 6 [/SUP], Maria Sole Chimenti[SUP] 2 [/SUP], Sergio Finazzi[SUP] 3 [/SUP], Antonino Mazzone[SUP] 7 [/SUP]


Affiliations
Abstract

The Coronavirus Disease 2019 (COVID-19) pandemic has raised concerns regarding its potential to induce autoimmune responses. Antinuclear antibodies (ANA) are hallmarks of systemic autoimmunity, and emerging evidence suggests their increased prevalence post-infection. This study aimed to assess ANA positivity rates and patterns of distribution before and after the onset of the pandemic in Lombardy, Italy. We conducted a historical analysis of 1879 matched Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) - Reverse Transcription Polymerase Chain Reaction (RT-PCR) and ANA records performed between March 2020 and December 2023. ANA positivity was assessed using indirect immunofluorescence (IIF) on Human Epithelial type 2 (HEp-2) cells and classified according to the International Consensus on ANA Patterns (ICAP). The extracted data were compared to the pre-pandemic period (2019). Cumulative risk analysis and Cox regression were used to evaluate associations among ANA and SARS-CoV-2 exposure, hospitalization, sex, and age. ANA positivity increased during the pandemic (42.4%) compared to 2019 (29.9%, p < 0.00001). Among SARS-CoV-2 positive individuals, ANA positivity was more frequent (12.9% vs 6%, OR: 2.31, p < 0.001). Cox regression confirmed that SARS-CoV-2 infection (HR:1.397), female sex (HR:1.458), hospitalization (HR 5.369) and age (HR:1.003) were independently associated with the risk of ANA positivity. Time-to-event analysis revealed that ANA positivity risk was higher in the first pandemic phases, following original and alfa variants of SARS-CoV-2 infections compared to delta and omicron variants. Nuclear anti-topo I-like [anti-cell (AC)-29] pattern was more prevalent in SARS-CoV-2 positive individuals. SARS-CoV-2 infection is associated with an increased cumulative risk of ANA positivity in the Lombardy population, especially in the earlier phases of the pandemic.

Keywords: ANA; COVID‐19; SARS‐CoV‐2 infection; autoimmunity.

 
Back
Top